Search academic texts

Information × Registration Number 0217U004789, 0115U000813 , R & D reports Title To improve the treatment of patients with non-Hodgkin diffuse large-B-lymphoma considering immunohistohimichnyh and molecular genetic markers popup.stage_title Head Kryachok Iryna, Registration Date 03-03-2017 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 Object of study - non-Hodgkin lymphoma, immunohistohimichni and molecular-genetic factors of the diseasePurpose - to determine the role of immunohistochemical and molecular genetic markers in the prognosis of non-Hodgkin diffuseB-lymphoma velykoklitynnyh optimize treatment of patients with non-Hodgkin diffuse lymphoma B-velykoklitynni with the latest chemotherapy. Methods and apparatus: morphological, immunohistochemical, clinical, statistical, the ultrasound device "Aloca", CT.The analysis of the prognostic value of immunohistochemical and molecular genetic markers for prognosis of the disease in 267 patients DVKL. There was no significant difference in the positive expression of markers such as Vcl-2, and CD30 MUM1 between groups of patients who responded to first-line therapy and primary refractory patients (84.7% and 82.1%, 70.8% and 60 0% 23 3% and 25.0% respectively, p> 0.05, respectively). There was a trend towards more frequent positive expression of CD10 in the group who responded to first-line therapy, 44.3% and 28.6% respectively, p> 0.05. The positive expression Vcl-6 significantly less frequently observed in patients refractory primary (67.6% and 36.4% respectively, p <0.05). Thus, the positive expression Vcl-6 was significantly more marked in patients who respond to treatment.The study of the role of the expression of the enzyme Indoleamine 2,3-dioksyhenazy (IDO), a clinical course DVVKL. The presence of IDO expression was significantly associated with advanced stage disease (p <0.05), ABC subtype and progression DVKKL (17.4% vs. 4.3%, p <0.05). The frequency of complete remission was significantly greater in the IDO-negative group compared to the IDO-positive DVKKL (34.7% vs. 21.7%, p <0.05). Found that IDO-positive expression is an important marker that is associated with a reduction in progression-free survival (PFS) in patients with DVKKL. 4-year PFS group IDO-positive patients was 50% compared with 73% in the IDO-negative patients (p = 0.002).The analysis of the immediate results of complex treatment of 69 patients with primary velykoklitynnu Mediastinal B-lymphoma (PMVL). Overall response rate in the group that received PCT scheme R-da-EPOCH, was100% in the group R-CHOP - 85%, p <0.01. Complete response (CR) was 81.8% and 50%, respectively. The maximum observation period was 62 months.The analysis of the effectiveness of treatment of 92 patients DVVKL, of unfavorable prognosis. The first group included patients who received treatment regimens CHOP, CNOP, CVP, COEP (26 people), the second - patients receiving chemotherapy scheme SNOER (25 people), the third - patients treated under the scheme R- CHOP, R-CNOP (36 people), the fourth - R-DA-EPOCH (4 patients). Product Description popup.authors Є. Кущевий А. Мартинчик К. Філоненко Крячок Ірина Анатоліївна О. Алексик Титоренко Ірина Борисівна Я. Степанішина popup.nrat_date 2020-04-02 Close